Research Topics
Genomes and GenesSpecies | O A KhanSummaryAffiliation: Wayne State University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosisOmar Khan
Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, D University Health Center, 4201 St Antoine, Detroit, MI 48201, USA
CNS Drugs 16:563-78. 2002..In a pharmaceutical environment with an estimated worldwide market of $US2.5 billion annually for RRMS, comparative studies are understandably provocative, but at the same time provide meaningful information to clinicians and patients...- Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?Omar Khan
Multiple Sclerosis Center and Neuroimaging Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
Neurology 68:S64-71; discussion S91-6. 2007..However, a consensus definition of "neuroprotection" applicable to MS needs to be established before such a tool can be validated and put to use... - A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosisO A Khan
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
Eur J Neurol 8:141-8. 2001..Despite some limitations of the study design, the results provide helpful clinical information regarding the relative efficacy of each therapy in mildly affected treatment-naïve RRMS patients... - Chronic cerebrospinal venous insufficiency and multiple sclerosisOmar Khan
Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, 4201 St Antoine, Detroit, MI 48323, USA
Ann Neurol 67:286-90. 2010..At present, invasive and potentially dangerous endovascular procedures as therapy for patients with MS should be discouraged until such studies have been completed, analyzed, and debated in the scientific arena... - What can be learned from open direct comparative trials in multiple sclerosis?Omar Khan
School of Medicine, Wayne State University, Detroit, MI, USA
J Neurol Sci 277:S25-8. 2009.... - Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosisOmar Khan
Multiple Sclerosis Clinical Research Center, Department of Neurology, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
J Neuroimaging 18:314-9. 2008..These data support the long-term effect of GA on maintaining axonal metabolic function and protection from sublethal injury as well as the feasibility of employing brain (1)H-MRS in long-term investigative studies in MS... - Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosisOmar Khan
Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
Mult Scler 11:646-51. 2005..These results support an in situ effect of GA therapy inside the CNS and suggest potential neuroprotective effects of GA... - Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI studyOmar Khan
MR Image Analysis Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
J Neurol Sci 312:7-12. 2012..To compare the long-term effect of disease-modifying therapies (DMT) on brain volume loss in relapsing-remitting MS (RRMS) patients... - A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapyO A Khan
Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
Mult Scler 7:349-53. 2001..106) who did not show a significant reduction. Despite limitations of the study design, the results provide helpful clinical information regarding the relative efficacy of each therapy in mildly affected treatment naive RRMS patients... - Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapyO A Khan
Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA
Mult Scler 7:185-8. 2001..Therapy with CTX was well tolerated. CTX may be of benefit in MS patients who experience rapid clinical worsening and are resistant to conventional therapy... - Intercaudate nucleus ratio as a linear measure of brain atrophy in multiple sclerosisC Caon
Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA
Neurology 60:323-5. 2003..67; p = 0.0001) and disease duration (r = 0.32; p < 0.01). Intercaudate ratio appears to be a reliable and reproducible linear measure of brain atrophy and correlates with disability and disease duration in MS... - Glatiramer acetate therapy for multiple sclerosis: a reviewJai Perumal
Wayne State University School of Medicine, Department of Neurology, 8D-UHC, Detroit, MI 48201, USA
Expert Opin Drug Metab Toxicol 2:1019-29. 2006.... - Multiple sclerosis susceptibility alleles in African AmericansB A Johnson
Department of Neurology, University of California, San Francisco, CA 94143, USA
Genes Immun 11:343-50. 2010..None of the tested variants showed results that were statistically inconsistent with the effects established in whites. The results are consistent with shared disease genetic mechanisms among individuals of European and African ancestry... - Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative studyAaron Boster
Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
Arch Neurol 66:593-9. 2009..To identify clinical and magnetic resonance imaging (MRI) features that distinguish progressive multifocal leukoencephalopathy (PML) from relapsing-remitting multiple sclerosis (RRMS)... - Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinicianAaron Boster
The Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine, and The Detroit Medical Center, Detroit, MI 48201, USA
Lancet Neurol 7:173-83. 2008..This Review describes the use of intense immunosuppressant drugs and natalizumab in patients with rapidly worsening MS and provides clinicians with guidelines for the use of these drugs in this patient group... - Acute transverse myelitis with normal brain MRI : long-term risk of MSJui Perumal
Multiple Sclerosis Center, Dept of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
J Neurol 255:89-93. 2008..To investigate the long-term risk of developing MS in patients presenting with acute transverse myelitis (ATM) and normal brain MRI scans at onset... - Predictors of subjective well-being among individuals with multiple sclerosisKelly A Ryan
Wayne State University, Detroit, MI 48202, USA
Clin Neuropsychol 21:239-62. 2007..The findings present a unique view of SWB among individuals with MS in the absence of acute exacerbation of the illness... - A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Ann Neurol 68:494-502. 2010..The current study was designed to confirm efficacy and further define safety and pharmacodynamics... - Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosisStacy J Caillier
Department of Neurology, University of California, San Francisco, CA 94143, USA
J Immunol 181:5473-80. 2008..The data underscore the power of the African American MS dataset to identify disease genes by association in a region of high linkage disequilibrium... - Mapping multiple sclerosis susceptibility to the HLA-DR locus in African AmericansJorge R Oksenberg
Department of Neurology, University of California at San Francisco, San Francisco, CA 94143 0435, USA
Am J Hum Genet 74:160-7. 2004..This finding is unlikely to be solely explained by admixture, since a substantial proportion of the susceptibility chromosomes from African American patients with MS displayed haplotypes consistent with an African origin... - Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLABruce A C Cree
Department of Neurology, University of California San Francisco, USA
Arch Neurol 66:226-33. 2009.... - Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imagingE Mark Haacke
Department of Radiology, Wayne State University, Detroit, Michigan 48201, USA
J Magn Reson Imaging 29:537-44. 2009..To investigate whether the variable forms of putative iron deposition seen with susceptibility weighted imaging (SWI) will lead to a set of multiple sclerosis (MS) lesion characteristics different than that seen in conventional MR imaging... - Fitness to drive in multiple sclerosis: awareness of deficit moderates riskKelly A Ryan
Wayne State University, Detroit, MI 48202, USA
J Clin Exp Neuropsychol 31:126-39. 2009..The findings have implications for interventions with persons with MS who drive... - Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosisPaul O'Connor
Division of Neurology, St Michael s Hospital, 30 Bond Street, Suite 3007S Shuter Wing, Toronto, Ontario, Canada
Mult Scler 11:568-72. 2005..In a six month, phase II clinical trial of patients with relapsing MS, natalizumab significantly reduced the formation of new gadolinium-enhanced (Gd+) lesions and the number of clinical relapses... - A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibilityDavid Reich
Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA
Nat Genet 37:1113-8. 2005..We describe here the first high-powered admixture scan, focusing on 605 African American cases and 1,043 African American controls, and report a locus on chromosome 1 that is significantly associated with multiple sclerosis... - Clinical inquiries. What nonpharmacological treatments are effective against common nongenital warts?Holly Abernethy
Shenandoah Valley Family Practice Residency, Department of Family Medicine, Virginia Commonwealth University, Front Royal, VA USA
J Fam Pract 55:801-2. 2006..CO2 laser, photodynamic therapy, pulsed dye laser (PDL), and Er:Yag laser therapies may also be effective for recalcitrant warts (SOR: C, based on observational cohort studies)... - Interferon-beta therapy for MS: the dilemma of having choicesOmar Khan
J Neurol Sci 222:1. 2004